International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided an update on the status of Parkinson's disease preclinical program. The program continues to progress on the plan developed with input from the FDA. To date no adverse events or pathological reactions have been observed in any of the completed preclinical pharmacology/toxicology studies. Results from these studies will form the basis of the regulatory submission requesting authorization to administer the drug in humans that ISCO expects to submit prior to the end of the year.

http://www.marketwired.com/press-rel...co-1952949.htm